Beyond Transactions: Building Sustainable Swiss–China Partnerships
Panel discussion summary
As the biotechnology world embraces multipolarity, new bridges need to be built between countries to create value. China and Switzerland are two heavyweights in the Global Life Sciences ecosystem. How could Swiss and Chinese companies use the strengths of each other to drive innovation and to establish a sustainable and mutually beneficial partnership model? Join our discussion with experienced cross-border biopharma bridge makers.
Date, time and room information
Monday, May 4, 14:30 - 15:15, room Shanghai 3+4
Moderation
| Name | Position | Institution |
|---|---|---|
| Peter Mozerov | Senior Manager, PhD | KPMG AG |
Panelists
| Name | Position | Institution |
|---|---|---|
| Kuno Gschwend | Deputy Head, Swiss Business Hub China, Embassy of Switzerland in China | Embassy of Switzerland in China |
| Bettina Ernst | VP Swiss Biotech Organisation & CEO Bernina BioInvest | Bernina BioInvest |
| Eric Adam | Chief Operating Officer | HAYA Therapeutics SA |
| Henri de Vlam | Senior Business Development Manager | Chime Biologics |
| Peter Zeng | Managing Director | Zeyu Capital |
KPMG AG
KPMG is a leading professional services firm in Switzerland, noted for clear and consistent solutions in audit, tax and advisory. Through its strong regional presence KPMG is close to you, helping you navigate today’s turbulences to find tomorrow’s answers.. KPMG’s Life Sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance.
Further information
Host and event manager:
Logistics and marketing partner:
